TMPA

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

TMPA 是一种核受体 Nur77 和 LKB1 相互作用拮抗剂。

TMPA is a nuclear receptor Nur77 and LKB1 interaction antagonist.

Cell Viability Assay Cell Line:T cells Concentration:10, 50, 100 μM Incubation Time:4 hResult:Significantly reduced T-cell RICD in a dose-dependent manner.Western Blot Analysis Cell Line:Hepatic LO2 cells Concentration:10, 20 μM Incubation Time:6 h Result:Led to an increase of LKB1 phosphorylation at Ser428.Western Blot Analysis Cell Line:Hepatic LO2 cells Concentration:5, 10, 20, 40, 80 μM Incubation Time:6 h Result:Increased the amount of phosphorylation of AmPKα in a dose- and time-dependent manner.Rescued the LKB1-AmPKα interaction by reducing the nur77-lKb1 interaction when at 10 μM.

Animal Model:Male C57BL/KsJ-Leprdb/Leprdb (db/db) mice (10-week-old; type II diabetic model).Dosage:50 mg/kg Administration:Intraperitoneal injection; single daily for 19 days.Result:Significantly reduced blood glucose at day 7 and persisted during the remainder of the test.Increased the amount of phosphorylated AMPKα in the liver of mice.

——

Others

Other Targets

Nur77|LKB1

——

——

1258275-73-8

380.48

C21H32O6

>98% (HPLC)

DMSO :90 mg/mL (236.54 mM); H2O : < 0.1 mg/mL (insoluble)

COC1=C(CC(OCC)=O)C(C(CCCCCCC)=O)=CC(OC)=C1OC

——

(-20℃)

With Ice Pack

≥ 2 years